Logo image of ASRT

ASSERTIO HOLDINGS INC (ASRT) Stock Fundamental Analysis

NASDAQ:ASRT - Nasdaq - US04546C2052 - Common Stock - Currency: USD

0.7819  -0.03 (-3.47%)

After market: 0.7833 +0 (+0.18%)

Fundamental Rating

3

ASRT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. ASRT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ASRT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ASRT had negative earnings in the past year.
In the past year ASRT had a positive cash flow from operations.
ASRT had negative earnings in 4 of the past 5 years.
ASRT had a positive operating cash flow in 4 of the past 5 years.
ASRT Yearly Net Income VS EBIT VS OCF VS FCFASRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M -300M

1.2 Ratios

ASRT has a Return On Assets (-24.81%) which is in line with its industry peers.
ASRT has a Return On Equity of -52.47%. This is comparable to the rest of the industry: ASRT outperforms 57.29% of its industry peers.
Industry RankSector Rank
ROA -24.81%
ROE -52.47%
ROIC N/A
ROA(3y)-29.94%
ROA(5y)-28.06%
ROE(3y)-64.41%
ROE(5y)-123.67%
ROIC(3y)N/A
ROIC(5y)N/A
ASRT Yearly ROA, ROE, ROICASRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

1.3 Margins

ASRT's Operating Margin has declined in the last couple of years.
ASRT's Gross Margin of 70.31% is fine compared to the rest of the industry. ASRT outperforms 75.52% of its industry peers.
In the last couple of years the Gross Margin of ASRT has declined.
ASRT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.31%
OM growth 3YN/A
OM growth 5Y-12.55%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-2.65%
ASRT Yearly Profit, Operating, Gross MarginsASRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

ASRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ASRT has been increased compared to 1 year ago.
Compared to 5 years ago, ASRT has more shares outstanding
The debt/assets ratio for ASRT has been reduced compared to a year ago.
ASRT Yearly Shares OutstandingASRT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
ASRT Yearly Total Debt VS Total AssetsASRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -2.40, we must say that ASRT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.40, ASRT is in line with its industry, outperforming 43.23% of the companies in the same industry.
The Debt to FCF ratio of ASRT is 1.91, which is an excellent value as it means it would take ASRT, only 1.91 years of fcf income to pay off all of its debts.
ASRT has a better Debt to FCF ratio (1.91) than 94.79% of its industry peers.
A Debt/Equity ratio of 0.30 indicates that ASRT is not too dependend on debt financing.
ASRT's Debt to Equity ratio of 0.30 is in line compared to the rest of the industry. ASRT outperforms 41.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 1.91
Altman-Z -2.4
ROIC/WACCN/A
WACC9.7%
ASRT Yearly LT Debt VS Equity VS FCFASRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 2.01 indicates that ASRT has no problem at all paying its short term obligations.
ASRT has a Current ratio of 2.01. This is comparable to the rest of the industry: ASRT outperforms 40.63% of its industry peers.
A Quick Ratio of 1.57 indicates that ASRT should not have too much problems paying its short term obligations.
ASRT's Quick ratio of 1.57 is on the low side compared to the rest of the industry. ASRT is outperformed by 60.42% of its industry peers.
Industry RankSector Rank
Current Ratio 2.01
Quick Ratio 1.57
ASRT Yearly Current Assets VS Current LiabilitesASRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for ASRT have decreased strongly by -177.66% in the last year.
ASRT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -25.80%.
ASRT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -13.38% yearly.
EPS 1Y (TTM)-177.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.48%
Revenue 1Y (TTM)-25.8%
Revenue growth 3Y12.68%
Revenue growth 5Y-13.38%
Sales Q2Q%-18.03%

3.2 Future

The Earnings Per Share is expected to grow by 21.95% on average over the next years. This is a very strong growth
Based on estimates for the next years, ASRT will show a decrease in Revenue. The Revenue will decrease by -0.40% on average per year.
EPS Next Y84.04%
EPS Next 2Y38.9%
EPS Next 3Y29.1%
EPS Next 5Y21.95%
Revenue Next Year-20.57%
Revenue Next 2Y-10.06%
Revenue Next 3Y-3.03%
Revenue Next 5Y-0.4%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ASRT Yearly Revenue VS EstimatesASRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
ASRT Yearly EPS VS EstimatesASRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ASRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ASRT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASRT Price Earnings VS Forward Price EarningsASRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

98.44% of the companies in the same industry are more expensive than ASRT, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 3.67
EV/EBITDA -3.39
ASRT Per share dataASRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

ASRT's earnings are expected to grow with 29.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.9%
EPS Next 3Y29.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ASRT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASSERTIO HOLDINGS INC

NASDAQ:ASRT (3/7/2025, 8:05:52 PM)

After market: 0.7833 +0 (+0.18%)

0.7819

-0.03 (-3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-11 2024-11-11/amc
Earnings (Next)03-12 2025-03-12/amc
Inst Owners29.96%
Inst Owner Change-6.44%
Ins Owners1.17%
Ins Owner Change4.78%
Market Cap74.66M
Analysts82
Price Target3.09 (295.19%)
Short Float %5.92%
Short Ratio11.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.76%
Min EPS beat(2)-22.55%
Max EPS beat(2)36.06%
EPS beat(4)1
Avg EPS beat(4)-735.02%
Min EPS beat(4)-2890.2%
Max EPS beat(4)36.06%
EPS beat(8)2
Avg EPS beat(8)-454.84%
EPS beat(12)5
Avg EPS beat(12)-284.68%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.31%
Min Revenue beat(2)-0.83%
Max Revenue beat(2)1.44%
Revenue beat(4)2
Avg Revenue beat(4)1.01%
Min Revenue beat(4)-4.36%
Max Revenue beat(4)7.79%
Revenue beat(8)5
Avg Revenue beat(8)-1.38%
Revenue beat(12)9
Avg Revenue beat(12)1.54%
Revenue beat(16)13
Avg Revenue beat(16)3.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)1.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.59
P/FCF 3.67
P/OCF 3.63
P/B 0.57
P/tB 1.96
EV/EBITDA -3.39
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)0.21
FCFY27.21%
OCF(TTM)0.22
OCFY27.55%
SpS1.32
BVpS1.37
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.81%
ROE -52.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.31%
FCFM 16.16%
ROA(3y)-29.94%
ROA(5y)-28.06%
ROE(3y)-64.41%
ROE(5y)-123.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)10.87%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-12.55%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-2.65%
F-Score5
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 1.91
Debt/EBITDA 5.13
Cap/Depr 1.03%
Cap/Sales 0.2%
Interest Coverage N/A
Cash Conversion 271.58%
Profit Quality N/A
Current Ratio 2.01
Quick Ratio 1.57
Altman-Z -2.4
F-Score5
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)16.92%
Cap/Depr(5y)10.44%
Cap/Sales(3y)3.59%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-177.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.48%
EPS Next Y84.04%
EPS Next 2Y38.9%
EPS Next 3Y29.1%
EPS Next 5Y21.95%
Revenue 1Y (TTM)-25.8%
Revenue growth 3Y12.68%
Revenue growth 5Y-13.38%
Sales Q2Q%-18.03%
Revenue Next Year-20.57%
Revenue Next 2Y-10.06%
Revenue Next 3Y-3.03%
Revenue Next 5Y-0.4%
EBIT growth 1Y-136.45%
EBIT growth 3YN/A
EBIT growth 5Y-24.25%
EBIT Next Year110.69%
EBIT Next 3Y30.79%
EBIT Next 5Y18.66%
FCF growth 1Y-63.65%
FCF growth 3YN/A
FCF growth 5Y-6.24%
OCF growth 1Y-63.28%
OCF growth 3YN/A
OCF growth 5Y-7.31%